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Despite recent advances in therapy, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only
curative option for a range of high-risk hematologic malignancies. However, acute graft-versus-host disease
(aGVHD) continues to limit the long-term success of HSCT, and new therapies are still needed. We previously
demonstrated that aGVHD depends on the ability of donor conventional T cells (Tcons) to express the lymph node
trafficking receptor, CC-Chemokine Receptor 7 (CCR7). Consequently, we examined the ability of cosalane, a
recently identified CCR7 small-molecule antagonist, to attenuate aGVHD in mouse HSCT model systems. Here we
show that the systemic administration of cosalane to transplant recipients after allogeneic HSCT did not prevent
aGVHD. However, we were able to significantly reduce aGVHD by briefly incubating donor Tcons with cosalane ex
vivo before transplantation. Cosalane did not result in Tcon toxicity and did not affect their activation or expansion.
Instead, cosalane prevented donor Tcon trafficking into host secondary lymphoid tissues very early after transplan-
tation and limited their subsequent accumulation within the liver and colon. Cosalane did not appear to impair
the intrinsic ability of donor Tcons to produce inflammatory cytokines. Furthermore, cosalane-treated Tcons
retained their graft-versus-leukemia (GVL) potential and rejected a murine P815 inoculum after transplantation.
Collectively, our data indicate that a brief application of cosalane to donor Tcons before HSCT significantly reduces
aGVHD in relevant preclinical models while generally sparing beneficial GVL effects, and that cosalane might rep-
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Despite recent advances in therapy, allogeneic hematopoi-
etic stem cell transplantation (HSCT) remains the sole curative
option for a range of high-risk hematologic malignancies. The
ultimate success of HSCT continues to be limited by acute graft-
versus-host disease (aGVHD), however, and new therapy
options are still needed. Our research group previously demon-
strated that aGVHD depends on the ability of donor “conven-
tional” nonregulatory T cells (Tcons) to express CC-Chemokine
Receptor 7 (CCR7), a G protein-coupled receptor critical for the
normal trafficking of lymphocytes and dendritic cells into lymph
nodes and the splenic white pulp [1,2]. Donor T cells knockedout at the CCR7 locus (CCR7¡/¡) generated greatly attenuated
aGVHD responses in multiple mouse HSCT model systems. Nev-
ertheless, CCR7¡/¡ Tcons retained their ability to mount benefi-
cial graft-versus-leukemia (GVL) antitumor immune responses,
and CCR7¡/¡ regulatory T cells were able to diminish aGVHD. In
addition, at least 2 studies involving human patients have linked
the proportion of CCR7-expressing T cells in the donor stem cell
product to the subsequent development of aGVHD [3,4].
Based on these data, we deemed CCR7 to be an attractive
therapy target and undertook a high-throughput screening
effort to identify small-molecule antagonists of the receptor.
This work revealed for the first time that cosalane, a compound
originally developed as a human immunodeficiency virus (HIV)
therapeutic, has an intrinsic ability to block human and murine
CCR7 function in vitro in response to both of its natural ligands,
CCL19 and CCL21 [5]. As a result, we explored the use of
cosalane as a new approach to prevent aGVHD in mouse HSCT
model systems and present our findings here.
Initial attempts to attenuate aGVHD through the systemic
administration of cosalane to mice post-transplantation were
unsuccessful, likely due to the compound's hydrophobicity and
high albumin binding. Nonetheless, we were able to signifi-
cantly reduce aGVHD by briefly incubating donor Tcons with
cosalane ex vivo before transplantation. Cosalane's effects
were observed in multiple strain combinations, including a
xenogeneic aGVHD model, were dose-dependent, and did not
appear to result in Tcon toxicity. Furthermore, cosalane did not
impair early stem cell engraftment when bone marrow (BM)
cells were also exposed to the compound before transplanta-
tion and appeared to spare GVL effects against murine P815
mastocytoma cells. Collectively, these data indicate that cosa-




C57BL/6 (“B6”; H-2b), B6xDBA/2 F1 (“B6D2”; H-2bxd), BALB/c (H-2d), and
NSG mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Enhanced green fluorescent protein (eGFP)-expressing B6 mice were gener-
ated as described previously [6]. CCR7¡/¡ mice that had been backcrossed
4 times onto a C57BL/6 background (B6.129P2-CCR7tm1Dgen) were obtained
from The Jackson Laboratory. These mice were further backcrossed in our lab-
oratory to 8 generations. All animal experiments were performed in accor-
dance with protocols approved by The University of North Carolina’s
Institutional Animal Care and Use Committee.
Transplantation Procedures
Recipient mice were irradiated on transplantation day -1. Recipients
were then administered T cell-depleted (TCD) BM cells with or without
CD25¡ column-purified conventional T cells (Tcons) to induce aGVHD as
described previously [7,8]. In brief, whole BM cells were collected from the
femurs and tibias of donor mice, lysed of RBCs using an ammonium chloride/
potassium carbonate buffer, and depleted of T cells by a negative selection
column purification process using anti-CD90.2 ferromagnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). For Tcon preparations, whole donor
splenocytes were lysed of RBCs and then applied to a total T cell isolation col-
umn (Cedarlane Laboratories, Burlington, ON, Canada). The flow-through was
then purified via a second negative selection approach. For this, the cells
were incubated with PE-conjugated antibodies against B220 (to remove any
residual contaminating B cells) and CD25 (to deplete regulatory T cells and
activated effector T cells), followed by anti-PE ferromagnetic beads. The cells
were then applied to a magnetic column (Miltenyi Biotec) and the final flow-
through collected. Following this procedure, the final Tcon inoculum consisted
of both CD25¡CD4+ and CD8+ T cells at an approximate 1:1 ratio.
For ex vivo cosalane incubations, cell populations were suspended in
serum/protein-free injectable saline. They were then incubated with cosalane
at varying concentrations or with an equal volume of DMSO vehicle for 1
hour at 37 °C before transplantation. The cells were then administered imme-
diately to recipients via tail vein injection. For xenograft experiments, human
peripheral blood mononuclear cells (PBMCs) were obtained from leukocytes
obtained from the Gulf Coast Regional Blood Center (Houston, TX) using a
Ficoll gradient.
Cosalane
Cosalane was obtained from Southern Research (Birmingham, AL) or pre-
pared in-house according to published protocols [9,10]. The cosalane deriva-
tives phenylalanine cosalane (p-cosalane) and tert-butyl cosalane (tb-
cosalane) were kind gifts from the Mark Cushman laboratory.
Tcon Proliferation Assay
Purified CD25¡ B6 Tcons were incubated with cosalane at the indicated
concentrations or an equal volume of DMSO vehicle for 1 hour at 37 °C. The
cells were then washed and cultured on 24-well plates that had been previ-
ously incubated overnight with anti-CD3 and anti-CD28 antibody at 10 mg/
mL. The cells were cultured for 72 hours in complete medium supplemented
with murine IL-2 at 100 IU/mL and then counted with a hemocytometer.
Organ eGFP Quantification
Recipients were euthanized, and their organs were removed. Individual
organs were immediately homogenized in PBS plus protease inhibitor with-
out any pooling of tissues, and absolute eGFP levels then determined with anenzyme-linked immunosorbent assay (ELISA) kit (Cell Biolabs, San Diego, CA)
as described previously [1].
Organ Cytokine Quantification
Recipient mice were euthanized, and their organs were removed and
homogenized. Total organ IFN-g and tumor necrosis factor levels were then
determined by ELISA (eBioscience, San Diego, CA).
P815 GVL Model and in Vivo Imaging
Luciferase-transfected P815 murine mastocytoma cells (H-2d) were a
kind gift from the Jonathan Serody laboratory. P815 cells were cultured and
then mixed with TCD BM cells before transplantation. A tumor dose of
2.5£ 104 P815 cells was used for all experiments. Recipients were then seri-
ally imaged using an IVIS Kinetic Optical real-time imaging system (Caliper
Life Sciences, Hopkinton, MA) to monitor for in vivo tumor growth twice
weekly. For imaging, recipients were dosed with 3 mg of D-luciferin (Perki-
nElmer, Waltham, MA) by i.p. injection at 10 minutes before the procedure.
Mice were then anesthetized with isoflurane during image acquisition.
Unless indicated otherwise, an exposure time of 4 seconds was used for all
images.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA). Survival curves were constructed using the Kaplan-Meier
method, and median survival times were compared using the log-rank test.
Unless indicated otherwise, continuous variables were compared using the
nonparametric Mann-Whitney U test. P values <.05 were considered signifi-
cant. Error bars represent SEM.
RESULTS
Cosalane Does Not Prevent aGVHDWhen Dosed Systemically
to Mice after Transplantation but Is Active ex Vivo
Initial work focused on whether cosalane (structure
depicted in Figure 1A) could limit aGVHD when dosed to
murine recipients after HSCT. For these experiments, we used
a standard C57BL/6 (“B6” H-2b) into C57BL/6 £ DBA2 (“B6D2”
H-2bxd) parent in an F1 model system. Based on the limited
existing literature describing cosalane administration to
rodents [11], we dosed the compound at 10 mg/kg via i.v.
injection on the day of transplantation and then again every 3
days for a total of 3 doses. Control mice were administered an
equivalent volume of DMSO vehicle. Mice were then followed
for overall survival and scored for aGVHD twice weekly using a
validated scoring system [12]. As shown in Figure 1B and C,
cosalane did not attenuate aGVHD and may have actually
worsened clinical outcomes.
Subsequent work has revealed that 10 mg/kg was an exces-
sively high dose to administer to irradiated recipients, and that
dosages of 2 to 5 mg/kg are much better tolerated. Neverthe-
less, given the technical challenges of repeated i.v. drug admin-
istration and cosalane supply considerations, we explored the
use of an ex vivo dosing strategy as an alternative means to
apply the compound. For these experiments, purified Tcons
were incubated with cosalane at 10 mg/mL (13 mM) or DMSO
vehicle diluted in saline at 37° C for 1 hour immediately before
transplantation. They were then mixed with untreated TCD
BM cells and administered to recipients by tail vein injection.
Recipients received no additional cosalane after transplanta-
tion. As depicted in Figure 1D and E, control mice given Tcons
incubated with DMSO in saline developed aggressive aGVHD
and demonstrated poor survival. In contrast, those receiving
Tcons incubated with cosalane in saline had lower aGVHD
scores and improved median survival times.
We next ensured that cosalane's ability to attenuate aGVHD
was not strain-dependent. For this work, we used a completely
MHC-mismatched B6 into BALB/c (H-2d) allograft model
(Figure 1F and G) and a human xenogeneic aGVHD system
(Figure 1H and I). Although cosalane's effects were not as com-
plete in these highly aggressive models, in both instances,
mice receiving cosalane-treated cells demonstrated prolonged
Figure 1. Donor Tcons exposed to cosalane ex vivo generate attenuated aGVHD responses. (A) The chemical structure of cosalane. (B and C) B6D2 mice were irradiated
to 950 rads on transplantation day -1. On day 0, recipients were administered 3£ 106 TCD B6 BM cells with or without 4£ 106 whole splenic B6 Tcons (CD25¡CD4+ and
CD25¡CD8+ T cells in a 1:1 ratio). Those mice receiving Tcons were dosed with cosalane at 10 mg/kg or with an equal volume of DMSO vehicle via i.v. injection on day 0
immediately before transplantation and then again on post-transplantation days +3 and +6. BM only, n = 2; all other treatment groups, n = 6. (B) Mice were followed
for survival. P > .05 for survival curve comparison between BM/Tcons and BM/Tcons with cosalane groups by the log-rank test. (C) Mice were scored for aGVHD twice
weekly using a validated scoring system. Recipients were assigned a score of 0 to 2 for 5 separate clinical parameters: weight loss, activity, kyphosis, fur ruffling, and
skin breakdown. Individual scores were then summed for a total score ranging from 0 to 10. P > .05 for aGVHD score comparison between BM/Tcons and BM/Tcons
with cosalane groups on day +40 by the Mann-Whitney test. (D and E) B6D2 mice were lethally irradiated on day -1. On day 0, recipients were administered 3£ 106
TCD B6 BM cells with or without 4£ 106 whole B6 Tcons. Donor Tcons were incubated ex vivo with cosalane diluted in normal saline at 10 mg/mL or an equal volume of
Figure 2. Cosalane does not affect Tcon proliferation in vitro and does not impair early donor lymphoid or myeloid engraftment after HSCT. (A) B6 Tcons were purified
and incubated with increasing concentrations of cosalane or equal volumes of DMSO vehicle in normal saline for 1 hour at 37° C. The cells were then washed and cul-
tured on 24-well plates precoated with anti-CD3 and anti-CD28 antibody in the presence of supplemental IL-2 for 72 hours. The cells per well were then quantified.
P > .05 for all cell number comparisons by the Mann-Whitney test. (B) Irradiated B6D2 recipients underwent transplantation with 3£ 106 eGFP+ B6 TCD BM cells
plus 4£ 106 eGFP+ B6 Tcons. The entire donor stem cell product (TCD BM cells plus Tcons) was incubated with either cosalane (15 mg/mL) or DMSO vehicle before trans-
plantation. On day +10, total numbers of donor (eGFP+) cells in the spleen were determined by flow cytometry. n = 5 mice per treatment group. P> .05 for all pairwise
cell number comparisons between DMSO and cosalane cell recipients by the Mann-Whitney test. (C and D) B6D2 recipients underwent transplantation as in (B) but
were followed for survival and scored for aGVHD. BM only, n = 4; all other treatment groups, n = 10. In (C), *P = .0006 for survival curve comparison between BM with
Tcons/DMSO and BM with Tcons/cosalane groups. In (D), *P = .0007 for aGVHD score comparison between BM with Tcons/DMSO and BM with Tcons/cosalane groups on
day +60.survival times. Collectively, these data indicate that a brief
incubation of donor immune cells with cosalane can reduce
aGVHD, and that this effect does not appear to be strain- or
species-specific.Cosalane Exposure Does Not Result in Cytotoxicity or Impair
BM Engraftment
Previous reports have indicated that cosalane is nontoxic to
cells in vitro, with a therapeutic index >1009. Nevertheless, we
set out to ensure that cosalane's ability to prevent aGVHD is
not the result of the drug killing the donor Tcon inoculum or
limiting these cells’ intrinsic ability to undergo activation and
expansion. Purified B6 Tcons were isolated as before and incu-
bated with cosalane at increasing concentrations ranging from
10 mg/mL (13 mM, the concentration used for the B6 into B6D2
survival experiment described in Figure 1D and E) to
30 mg/mL (39 mM) or an equal volume of DMSO diluted in nor-
mal saline. The cells were then washed, placed on 24-well
plates precoated with anti-CD3 and anti-CD28 immunoglobu-
lin, and cultured for 72 hours in medium containing supple-
mental IL-2. Following incubation, all the Tcon groups exhibited
robust growth in vitro, and no differences in cell numbers
were noted after the culture period (Figure 2A).DMSO in normal saline for 1 hour at 37° C. The cells were then mixed with untreated
injection. Mice were then followed for survival and scored for aGVHD. BM only, n = 4;
survival curve comparison between BMwith Tcons/DMSO and BM with Tcons/cosalane g
with Tcons/DMSO and BMwith Tcons/cosalane on day +60. (F and G) BALB/c mice were i
TCD B6 BM cells with or without 5£ 105 whole B6 Tcons incubated ex vivo with cosala
saline. Mice were then followed for survival and scored for aGVHD. BM only, n = 3; a
between BM with Tcons/DMSO and BM with Tcons/cosalane groups. In (G), P > .05 for aG
lane groups on day +47. (I and J) NSG mice were irradiated to 200 rads on day -1. O
DMSO or cosalane at 15 mg/mL. Mice were then followed for survival and scored for a
parison. In (J), P > .05 for aGVHD score comparison on day +30.Following up on these data, we determined whether cosa-
lane exposure could potentially cause injury to hematopoietic
stem cells if BM were also exposed to cosalane ex vivo. Notably,
this situationwould be potentially relevant to human transplan-
tation, in which the donor stem cell product is typically not sep-
arated into separate cellular components before administration.
Purified Tcons and TCD BM cells were obtained from B6 donors
transgenic for eGFP, mixed together, and then incubated with
cosalane or DMSO. The cells were subsequently administered to
irradiated B6D2 recipients, and early BM and Tcon engraftment
then determined by flow cytometry within the host spleen on
post-transplantation day +10. Donor-derived cells were distin-
guished from residual host cells by virtue of their eGFP positiv-
ity. As shown in Figure 2B, cosalane exposure did not produce
any differences in donor monocyte, neutrophil, T cell, or B cell
numbers in the spleen at this time point.
We next determined whether cosalane treatment of the
entire stem cell product (BM plus Tcons) would limit the com-
pound's ability to reduce aGVHD or potentially result in
delayed mortality due to eventual BM failure. As depicted in
Figure 2C and D, cosalane treatment of the whole stem product
appeared to attenuate aGVHD at least as well as what was
observed previously with the isolated treatment of Tcons alone.
Furthermore, no clinical signs of delayed BM failure wereTCD B6 BM cells and administered immediately to recipient mice by tail vein
, BM with Tcons/DMSO, n = 8; BM with Tcons/cosalane n = 8. In (D), *P = .044 for
roups by the log-rank test. In (E), *P = .026 for aGVHD comparison between BM
rradiated to 800 rads on day -1. On day 0, recipients were administered 5£ 106
ne at 15 mg/mL in normal saline alone or an equal volume of DMSO vehicle in
ll other treatment groups, n = 10. In (F), *P = .01 for survival curve comparison
VHD score comparison between BM with Tcons/DMSO and BM with Tcons/cosa-
n day 0, recipients were given 7£ 106 human PBMCs incubated ex vivo with
GVHD. n = 5 in both treatment groups. In (I), *P = .0064 for survival curve com-
observed, with 90% of the cosalane group surviving to the end
of the study observation period. Collectively, these data indi-
cate that cosalane does not induce any apparent cytotoxicity in
vitro at doses up to 39 mM, and that a whole marrow product
can be safely exposed to compound without any loss of com-
pound efficacy or apparent impairment in myeloid or lym-
phoid engraftment.
Cosalane Affects Donor Tcon Function in a Dose-Dependent
Fashion and Is More Potent than 2 Similar Structural
Derivatives
We next set out to formally determine whether cosalane's
effects are dose-dependent. For this work, we incubated puri-
fied B6 Tcons with DMSO or increasing concentrations of cosa-
lane ex vivo: 10 mg/mL (13 mM), 20 mg/mL (26 mM), and 30 mg/
mL (39 mM). The cells were then mixed with untreated TCD
B6 BM cells and administered to irradiated B6D2 recipients.
Recipient mice were followed for survival and scored for
aGVHD twice weekly. As depicted in Figure 3A and B, we
observed improved transplantation outcomes with increasing
dosages of cosalane during the preincubation step.
Building on these data, we went on to repeat transplants
using a B6 into BALB/c completely MHC mismatched allograft
model (Figure 3C and D) and a human PBMC into NSG xenoge-
neic system (Figure 3E and F) with higher compound doses.
Compared with the outcomes observed previously (Figure 1F-
I), cosalane's effects were more complete and more durable,
with most recipients surviving to the end of the study period.
Thus, at higher dosages, cosalane allowed for nearly complete
aGVHD protection in 3 separate model systems.
Our laboratory subsequently evaluated the activity of 2 cosa-
lane derivatives, phenylalanine cosalane (p-cosalane) and
tert-butyl cosalane (tb-cosalane), in which the amino acid phe-
nylalanine or a tert-butyl group respectively is conjugated to
each of cosalane's two carboxylic acid groups. For this work, we
used a B6 into B6D2 model system and incubated donor Tcons ex
vivo with identical doses of cosalane, p-cosalane, tb-cosalane, or
DMSO vehicle before transplantation. Recipients were then fol-
lowed for survival and scored for aGVHD. As depicted in
Figure 3G and H, neither derivative appeared to be as active as
the parent compound. Given the dose-dependent nature of
cosalane's aGVHD protective effects, however, we repeated this
experiment with higher concentrations of each derivative. As
shown in Figure 3I and J, both structures were able to improve
median survival times at higher doses, with recipients of p-cosa-
lane-treated Tcons showing the lowest aGVHD scores. Collec-
tively, these data indicate a class effect for this family of
compounds. Nevertheless, neither of the derivatives was as
potent as the parent structure, suggesting that the identity of
the compound's hydrophilic head group is particularly relevant
to the drug's ability to ameliorate aGVHD after HSCT.
Cosalane Limits aGVHD by Blocking Tcon Accumulation in the
Colon and Liver, with Minimal Action on Donor BM Cells
Most of our allogeneic transplantation experiments up to
this point had involved the treatment of purified donor Tcons
composed of a mixture of CD25¡CD4+ and CD25¡CD8+ cells
(Figures 1D-G and 3A-D). In treating this particular population,
we were able to consistently reduce aGVHD and improve sur-
vival, thereby establishing donor Tcons as a critical cosalane
drug target. However, previous studies have shown that donor
BM-derived antigen-presenting cells, particularly CCR7+ den-
dritic cells, play a role in augmenting the aGVHD process
[13,14]. Furthermore, in our own experiments in which donor
BM cells and donor Tcons were exposed to cosalanepretransplantation (Figure 2C and D), we achieved excellent
long-term aGVHD control. As a result, we questioned whether
recipient mice might derive a benefit from the isolated treat-
ment of donor BM cells alone or a synergistic benefit from the
combined treatment of donor Tcons and BM.
To formally evaluate this possibility, we performed a B6
into B6D2 haplotype-matched transplantation in which we
pretreated donor BM cells, donor Tcons, both populations, or
neither population with cosalane before HSCT. Given our find-
ing that cosalane's effects are dose-dependent, each cell popu-
lation was incubated in an identical concentration of drug.
Recipients were then followed for survival and scored for
aGVHD twice weekly. As shown in Figure 4A and B, the isolated
treatment of purified donor BM cells alone did not significantly
improve outcomes. Conversely, the isolated treatment of donor
Tcons once again resulted in substantial attenuation of aGVHD,
with 100% survival in this instance. Notably, the combined
treatment of BM cells and Tcons did not appear to further
reduce aGVHD scores. Nevertheless, the combination group
appeared to do equally well, with 100% of recipients surviving
to the end of the study period. Collectively, these data confirm
our previous findings that cosalane can be safely administered
to a whole donor stem cell product (BM cells plus T cells), but
also indicate that cosalane's protective effects occur primarily
via action on mature Tcons contained in the graft.
Given that cosalane appears to act primarily on Tcons, we
elected to focus on this population in the remainder of our stud-
ies. Because cosalane is known to block CCR7 in vitro [5], we
hypothesized that the compoundwould limit donor Tcon traffick-
ing to host lymph nodes after transplantation [1,2]. To evaluate
this, eGFP+ B6 Tcons were incubated with cosalane or DMSO vehi-
cle and then transplanted with untreated eGFP¡ B6 TCD BM cells
into irradiated eGFP¡ B6D2 recipients. On day +7, recipients
were killed and their secondary lymphoid tissues (SLTs; mesen-
teric lymph nodes [MLNs], inguinal lymph nodes [ILNs], and
spleen) were removed along with 3 important aGVHD target
organs: colon, lung, and liver. These tissues were then homoge-
nized, and donor Tcon accumulation in each site was compared
between recipients of cosalane and recipients of vehicle-treated
cells using an anti-eGFP ELISA approach. As depicted in
Figure 4C, no differences in donor Tcon accumulation were noted
in either host SLTs or aGVHD target organs at this time point.
Subsequent to this, we performed an identical transplanta-
tion but harvested recipient organs on day +14, a later time
point at which clinical differences between the 2 treatment
groups are typically more prominent (Figure 4D). As before, we
found no differences in donor Tcon accumulation within host
lymphoid sites; however, by the second post-transplantation
week, we detected a significant reduction in donor Tcons within
the colon and liver. Taken together, these experiments did not
suggest any generalized deficit in Tcon expansion, as the eGFP
signal was similar in a majority of sites in both treatment
groups. Instead, cosalane was specifically limiting donor Tcon
accumulation in 2 critical aGVHD target organs while having
surprisingly little impact on their expansion within the SLTs.
Following up on these data, we evaluated cosalane's effects
on inflammatory cytokine production after HSCT. No differen-
ces in total TNF or IFN-g levels were noted in the spleen, MLN,
ILNs, or lung on either post-transplantation day +7 (Figure 4E)
or day +14 (Figure 4F). Conversely, consistent with our Tcon in
vivo trafficking data, both TNF and IFN-g levels were signifi-
cantly reduced in the host colon on day +14 in the cosalane
treatment group (Figure 4F). Collectively, these data do not
support any overall deficiency in inflammatory cytokine pro-
duction following cosalane exposure; rather, they indicate
Figure 3. Cosalane functions in a dose-dependent fashion and is more potent than 2 structurally similar derivatives. (A and B) B6D2 mice were lethally irradiated on
day -1. On day 0, recipients were administered 3£ 106 TCD B6 BM cells with or without 4£ 106 B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle or
cosalane diluted in normal saline at increasing concentrations ranging from 10 mg/mL to 30 mg/mL. The cells were then mixed with untreated TCD B6 BM cells and
administered immediately to recipient mice by tail vein injection. Mice were then followed for survival and scored for aGVHD. BM only, n = 4; all other treatment
groups, n = 10. In (A), *P = .020 for survival curve comparison between BMwith Tcons/cosalane 10 mg/mL and BM with Tcons/cosalane 20 mg/mL; **P = .0165 for survival
curve comparison between BM with Tcons/cosalane 10 mg/mL and BM with Tcons/cosalane 30 mg/mL. In (B), P > .05 for aGVHD score comparison between BM with
that, with the exception of the liver, organ cytokine level dif-
ferences between the cosalane and control groups generally
parallel differences in the number of infiltrating donor Tcons.Cosalane Prevents aGVHD in a CCR7-Associated Manner
As noted previously, our initial premise for using cosalane to
attenuate aGVHD was based on its demonstrable antagonistic
effects on CCR7, a chemokine receptor critical for T cell traffick-
ing into SLTs [2]. However, our in vivo trafficking data indicated
a minimal impact on the ability of donor Tcons to accumulate
within the host spleen or lymph nodes on post-transplantation
days +7 and +14 and suggested that cosalane's anti-aGVHD
properties actually might be CCR7-independent. To more defini-
tively ascertain the extent to which cosalane's protective
effects are linked to CCR7, we induced lethal aGVHD with
CCR7¡/¡ Tcons, reasoning that if CCR7 were indeed critical for its
action, then the drug should be less active in this setting. Nota-
bly, aGVHD is not entirely prevented by the genetic absence of
CCR7 on donor Tcons; rather, aGVHD is greatly attenuated com-
pared with that induced by an equivalent dose of wild-type
(WT) donor Tcons. We previously found that the degree of
aGVHD attenuation observed in the absence of CCR7 is some-
what model-dependent, with outcome differences less pro-
nounced with higher degrees of MHC mismatch between the
donor and recipient strains [1]. As a result, for this work we
chose an aggressive, completely MHC-mismatched B6 into
BALB/c system. In addition, we performed dose-finding work
with CCR7¡/¡ B6 donor mice to arrive at an appropriate donor
Tcon dose that would consistently induce lethal aGVHD at an
intensity/severity approximating what is typically observed
with 5£ 105 WT cells. After evaluating a range of different
doses, we identified a donor Tcon inoculum of 3£ 106
CCR7¡/¡ B6 Tcons per recipient as optimal. CCR7¡/¡ Tcons were
pretreated with DMSO or cosalane ex vivo at 15 mg/mL, the
same dose that we used for the survival studies depicted in
Figure 1F and G using an identical B6 into BALB/c strain combi-
nation. As shown in Figure 5A and B, and in contrast to what we
observed with WT B6 donor Tcons, cosalane appeared to be
completely inactive at this dose.
We previously found cosalane to afford nearly complete
aGVHD protection in a B6 into BALB/c system at a higher incu-
bation concentration of 30 mg/mL (Figure 3C and D). As a result,
we repeated our CCR7¡/¡ B6 into BALB/c transplantation, but
preincubated the donor Tcons with an identical cosalane con-
centration of 30 ug/mL. As shown in Figure 5C and D, again
cosalane's effects were much less complete in the absence of
donor Tcon CCR7, even at a higher drug dose. Nevertheless,Tcons/cosalane 10 mg/mL and BM with Tcons/cosalane 20 mg/mL or BM with Tcons/cosala
day -1. On day 0, recipients were administered 5£ 106 TCD B6 BM cells with or witho
cosalane diluted in normal saline at 30 mg/mL. The cells were then mixed with untre
vein injection. Mice were then followed for survival and scored for aGVHD. BM on
*P < .0001 for survival curve comparison between BM with Tcons/DMSO and BM with
BMwith Tcons/DMSO and BMwith Tcons/cosalane groups on day +35. (E and F) NSG mic
7£ 106 human PBMCs that had been incubated ex vivo with DMSO or cosalane at 35
per treatment group. In (E), *P = .0049 for survival curve comparison. In (F), P > .05 fo
human PBMCs/cosalane group on day +45. (G and H) B6D2 mice were lethally irradia
with or without 4£ 106 B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehic
The cells were then mixed with untreated TCD B6 BM cells and administered immediat
and scored for aGVHD. BM only, n = 2; all other treatment groups, n = 4. In (G), *P = .0
Tcons/cosalane; P > .05 for survival curve comparison between BM with Tcons/DMSO
aGVHD score comparison between BM with Tcons/DMSO and BM with Tcons/p-cosa
cosalane on day +38. (I and J) B6D2 mice were lethally irradiated on day -1. On day 0,
B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle or p-cosalane or tb-c
untreated TCD B6 BM cells and administered immediately to recipient mice by tail v
only, n = 2; all other treatment groups, n = 5. In (I), *P = .0269 for survival curve compa
for survival curve comparison between BM with Tcons/DMSO and BM with Tcons/tb
Tcons/DMSO and BMwith Tcons/p-cosalane on day +41; **P = .0238 for aGVHD score compcosalane's protective effects were not entirely abrogated in
this case, with recipients of cosalane-treated CCR7¡/¡ B6 Tcons
demonstrating longer survival times and a trend toward lower
aGVHD scores compared with control mice. Collectively, these
data indicate that cosalane does appear to exert its protective
effects in a CCR7-associated manner; however, its modest
residual efficacy even in the absence of the receptor suggests
activity against additional target(s) yet to be determined.
In light of these survival data linking cosalane's ability to
attenuate aGVHD to CCR7, we revisited our initial hypothesis
that cosalane might impair donor Tcon trafficking into host
lymphoid sites. Our previous in vivo trafficking measurements
performed on post-HSCT days +7 and +14 (Figure 4C and D)
failed to show any differences in lymphoid accumulation
between cosalane and vehicle-treated Tcons. It should be noted,
however, that significant Tcon activation and expansion would
have already occurred by these time points, and that donor
immune cells could have recirculated back into the lymph
nodes via the afferent lymphatics. Furthermore, previous
reports have indicated that a partial deficiency in CCR7 signal-
ing can result in delayed but paradoxically increased T cell
expansion within lymph nodes over time owing to altered neg-
ative feedback mechanisms [15]. As a result, subtle effects of
cosalane on early lymphocyte trafficking out of the blood-
streammight have been overlooked.
To more definitively ascertain whether cosalane could
impair donor Tcon homing into host SLTs, we transplanted cosa-
lane- or DMSO-treated eGFP+ Tcons into irradiated B6D2 recipi-
ents and then harvested their organs for analysis by anti-eGFP
ELISA after only 36 hours, a time at which Tcon expansion and/or
recirculation would be minimal. Of note, an ELISA approach is
extremely sensitive and allows for direct eGFP quantitation
within postirradiated atrophied lymphoid sites without the
need for pooling of tissues. As shown in Figure 5E, at this time
point, we detected significant reductions in donor Tcons within
the spleen, ILNs, and MLNs in those mice given cosalane-treated
cells. Thus, cosalane does indeed limit the trafficking of donor
Tcons into host lymphoid sites early after transplantation. The
observed differences in the number of donor Tcons within SLTs
become less prominent over time, however, and are no longer
detectable by the end of the first week post-transplantation.Cosalane Treatment of Donor Tcons before HSCT Limits aGVHD
but Spares GVL Effects
Any therapy that reduces aGVHD also has the potential to
impair beneficial GVL effects. Consequently, we evaluated
cosalane's effects on GVL immunity using a well-describedne 30 mg/mL on day +60. (C and D) BALB/c mice were irradiated to 800 rads on
ut 5£ 105 B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle or
ated TCD B6 BM cells and administered immediately to recipient mice by tail
ly, n = 4; BM with Tcons/DMSO, n = 9; BM with Tcons/cosalane, n = 10. In (C),
Tcons/cosalane groups. In (D), *P < .0001 for aGVHD score comparison between
e were irradiated to 200 rads on day -1. On day 0, recipients were administered
mg/mL. Mice were then followed for survival and scored for aGVHD. n = 6 mice
r aGVHD score comparison between the human PBMCs/DMSO group and the
ted on day -1. On day 0, recipients were administered 3£ 106 TCD B6 BM cells
le or cosalane, p-cosalane, or tb-cosalane diluted in normal saline at 20 mg/mL.
ely to recipient mice by tail vein injection. Mice were then followed for survival
40 for survival curve comparison between BM with Tcons/DMSO and BM with
and BM with Tcons/p-cosalane or BM with Tcons/tb-cosalane. In (H), P > .05 for
lane on day +62 and between BM with Tcons/DMSO and BM with Tcons/tb-
recipients were administered 3£ 106 TCD B6 BM cells with or without 4£ 106
osalane diluted in normal saline at 30 mg/mL. The cells were then mixed with
ein injection. Mice were then followed for survival and scored for aGVHD. BM
rison between BM with Tcons/DMSO and BM with Tcons/p-cosalane; **P = .0039
-cosalane. In (J), *P = .0079 for aGVHD score comparison between BM with
arison between BMwith Tcons/DMSO and BMwith Tcons/tb-cosalane on day +41.
Figure 4. Cosalane limits donor Tcon accumulation within the liver and colon. (A and B) B6D2 mice were lethally irradiated on day -1. On day 0, recipients were
administered 3£ 106 TCD B6 BM cells with or without 4£ 106 B6 Tcons. Donor TCD BM cells, donor Tcons, both cell populations, or neither were incubated ex vivo
with cosalane at 15 mg/mL for 1 hour before transplantation. Cells not treated with cosalane were incubated with an equal volume of DMSO vehicle. Mice were then
followed for survival and scored for aGVHD. BM only, n =2; all other treatment groups, n = 5. In (A), P > .05 for survival curve comparison between BM/DMSO with
Tcons/DMSO and BM/cosalane with Tcons/DMSO groups; *P = .0018 for survival curve comparison between BM/DMSO with Tcons/DMSO and BM/DMSO with Tcons/cosa-
lane groups; **P = .0018 or survival curve comparison between BM/DMSO with Tcons/DMSO and BM/cosalane with Tcons/cosalane groups. In (B), P > .05 for aGVHD
score comparison between BM/DMSO with Tcons/DMSO and BM/cosalane with Tcons/DMSO groups on day +40. (C and D) B6D2 mice were lethally irradiated on day
Figure 5. Cosalane functions in a CCR7-associated manner and alters donor Tcon trafficking into SLT early after transplantation. (A and B) BALB/c mice were lethally
irradiated on day -1. On day 0, recipients were administered 5£ 106 TCD B6 BM cells with or without 3£ 106 CCR7¡/¡ B6 Tcons. Donor Tcons were incubated ex vivo
with DMSO vehicle or cosalane diluted in normal saline at 15 mg/mL. The cells were then mixed with untreated TCD B6 BM cells and administered immediately to
recipient mice by tail vein injection. Mice were then followed for survival and scored for aGVHD. BM only, n = 2; all other treatment groups, n = 6. In (A), P > .05 for
survival curve comparison between BM with CCR7¡/¡ Tcons/DMSO and BM with CCR7¡/¡ Tcons/cosalane groups. In (B), P > .05 for aGVHD score comparison between
BM with CCR7¡/¡ Tcons/DMSO and BM with CCR7¡/¡ Tcons/cosalane groups on day +24. (C and D) BALB/c mice underwent transplantation as in (A) and (B); however,
donor CCR7¡/¡ B6 Tcons were incubated ex vivo with DMSO vehicle or cosalane diluted in normal saline at 30 mg/mL. BM only, n = 2; all other treatment groups, n = 9.
In (C), *P = .0481 for survival curve comparison between BM with CCR7¡/¡ Tcons/DMSO and BM with CCR7¡/¡ Tcons/cosalane groups. In (D), P > .05 for aGVHD score
comparison between BM with CCR7¡/¡ Tcons/DMSO and BM with CCR7¡/¡ Tcons/cosalane groups on day +67. (E) B6D2 mice were lethally irradiated on day -1. On day
0, recipients were administered 5£ 106 eGFP+ B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle or cosalane diluted in normal saline at 15 mg/mL.
Recipient mice were killed after 36 hours, and lymphoid organs were subsequently harvested and homogenized. Total eGFP levels were then determined by ELISA.
n = 6 per treatment group. *P = .0043 for spleen comparison between DMSO and cosalane groups by Mann-Whitney test; **P = .0022 for ILN comparison; ***P = .0022
for MLN comparison.P815 murine mastocytoma (H-2d) leukemia model. Here B6D2
mice were lethally irradiated and then given 3£ 106 TCD B6
BM cells containing 25,000 luciferase-transfected P815 cells
with or without 4£ 106 B6 Tcons to drive a GVL response. One-
half of those mice receiving BM/tumor plus Tcons received Tcons
incubated with DMSO, and the other half received cosalane-
treated Tcons. Recipients were subsequently evaluated by serial
in vivo imaging to monitor tumor growth in each treatment
group. In most instances, recipient mortality could be reason-
ably attributed to tumor versus aGVHD based on the tumor
burden by imaging and clinical aGVHD scores at the time of
death. As depicted in Figure 6, all the mice given BM cells plus
tumor without Tcons demonstrated aggressive tumor growth,-1. On day 0, recipients were administered 3£ 106 TCD eGFP¡ B6 BM cells plus 4£ 106
lane diluted in normal saline at 15 mg/mL. The cells were then mixed with untreated
injection. Recipient mice were subsequently killed on day +7 (C) or day +14 (D). Lymp
quently harvested and homogenized. Total eGFP levels were then determined using an
parisons on day +7. In (D), *P = .0003 for colon comparison between DMSO and cosalan
B6D2 mice underwent transplantation as in (C) and (D), and their organs were remov
TNF (right panels) was then determined by ELISA. n = 7 per treatment group. In (E), *
test. In (F), *P = .0015 for total IFN-g comparison in the colon on day +14; **P = .0002 fowith 100% malignancy-related mortality. All the mice given
BM/tumor plus DMSO-treated Tcons (BM/Tcons) rejected the
P815 inoculum but developed aggressive aGVHD. In contrast,
the mice given BM/tumor plus cosalane-treated Tcons (BM/
cosalane Tcons) demonstrated substantial suppression of tumor
growth and the longest overall survival times.
In GVL transplantation experiments, the aGVHD control
group (BM/tumor/DMSO-treated Tcons in this instance) fre-
quently succumbs to lethal aGVHD before any tumor growth
can occur. As a result, it is often difficult to compare longer-
term GVL effects between these mice and mice given BM/Tcons
plus an anti-aGVHD therapy (BM/tumor/cosalane-treated
Tcons). To address this, we performed a similar experiment buteGFP+ B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle or cosa-
TCD B6 BM cells and administered immediately to recipient mice by tail vein
hoid organs (left panels) and aGVHD target organs (right panels) were subse-
anti-eGFP ELISA. n = 7 per treatment group. In (C), P > .05 for all pairwise com-
e groups by the Mann-Whitney test; **P = .0006 for liver comparison. (E and F)
ed and homogenized on day +7 (E) or day +14 (F). Total IFN-y (left panels) and
P = .038 for total TNF comparison in the liver on day +7 by the Mann-Whitney
r total TNF comparison in the colon on day +14.
Figure 6. Cosalane-treated Tcons remain capable of GVL effects. B6D2 mice were lethally irradiated on day -1. On day 0, recipients were administered 3£ 106 TCD
B6 BM cells and 2.5£ 104 luciferase+ P815 murine mastocytoma cells (H-2d) with or without 4£ 106 B6 Tcons. Donor Tcons were incubated ex vivo with DMSO vehicle
or cosalane diluted in normal saline at 15 mg/mL. The cells were then mixed with untreated BM/tumor cells and administered immediately to recipient mice by tail
vein injection. Mice were then serially imaged twice weekly following i.p. injection of luciferin. Selected imaging points are depicted. Recipient mortality was attrib-
uted to tumor versus aGVHD based on the tumor burden by imaging and clinical aGVHD scores at the time of death. Exposure time, 4 seconds for all panels. n = 5 per
treatment group.reduced the dose of Tcons in the DMSO control group by 50%.
Specifically, mice received 3£ 106 TCD BM cells plus 25,000
P815 cells, BM/tumor plus 2£ 106 DMSO-treated Tcons, or BM/
tumor plus 4£ 106 cosalane-treated Tcons. As shown in Figure 7,
all mice given BM alone once again died from malignancy.
Three of the 6 mice given 2£ 106 DMSO Tcons died from malig-
nancy, and 3 died from aGVHD. Three of the 6 mice given4£ 106 cosalane-treated Tcons died from aGVHD, and none
succumbed to malignancy. Thus, in this experiment, cosalane-
treated Tcons generated an aGVHD response roughly equivalent
to one-half as many untreated Tcons while simultaneously
producing a stronger GVL effect. These data indicate that cosa-
lane was able to separate aGVHD effects from GVL effects in
this model system.
Figure 7. Cosalane treatment of donor Tcons separates aGVHD from GVL effects in a P815 tumor model. B6D2 mice were lethally irradiated on day -1. On day 0, recipi-
ents were administered 3£ 106 TCD B6 BM cells and 2.5£ 104 luciferase+ P815 murine mastocytoma cells. Some recipients also received 2£ 106 DMSO-treated B6
Tcons or 4£ 106 cosalane-treated B6 Tcons (15 mg/mL). Mice were then serially imaged twice weekly following i.p. injection of luciferin. Selected imaging points are
depicted. Exposure time, 4 seconds for all panels. The “mixed” cage on the far right contained one mouse each of the BM/P815 only, BM/P815 plus DMSO Tcons, and
BM/P815 plus cosalane Tcons groups; n = 6 per treatment group.DISCUSSION
Cosalane was originally developed as an HIV therapeutic.
The drug initially appeared to be quite promising, with activity
against multiple strains of resistant HIV and a range of envel-
oped viruses relevant to the HSCT setting, including cytomega-
lovirus and herpes simplex virus [16]. Cosalane has never been
used clinically, however, likely owing to several important char-
acteristics of the molecule. Cosalane exhibits very poor oral bio-
availability [11], which generally precludes its use as a viable
anti-HIV therapy. Furthermore, although cosalane can be suc-
cessfully administered i.v., it exhibits high albumin avidity and a
propensity to accumulate within the liver [11,17]. Despite these
drawbacks, however, the HSCT setting represents a unique clini-
cal scenario in which cosalane could be effectively used. Specifi-
cally, HSCT allows for the ex vivo manipulation of donor cells
before administration. Thus, the bioavailability and pharmacoki-
netic concerns that thus far have limited cosalane's clinical
translation would be much less of an issue.At this time, we envision that cosalane could be applicable
to the stem cell transplantation field in one of several ways.
First, cosalane could be used as aGVHD prophylaxis at the time
of HSCT. Based on our data, it would appear that an entire
hematopoietic stem cell product could be safely treated with
cosalane without any detrimental effects on early engraftment
or long-term BM persistence. Second, because cosalane dimin-
ishes aGVHD by acting primarily on donor Tcons, it could be
used to limit the aGVHD potential of donor lymphocyte infu-
sion (DLI) administered to boost donor chimerism and/or stave
off early malignancy recurrence. Our own data suggest that
cosalane selectively limits the ability of donor Tcons to mediate
aGVHD effects while appearing to spare their GVL potential.
Although a precise mechanism for this separation of immune
effects is not entirely clear, we suspect that the difference is
primarily spatial in nature. Specifically, cosalane ultimately
limits the accumulation of alloreactive Tcons within aGVHD tar-
get organs without affecting their intrinsic activation,
expansion, or ability to mediate inflammatory cytokine pro-
duction. Early after transplantation, cosalane does reduce
donor Tcon accumulation within host lymphoid tissues, impor-
tant potential sites for leukemia growth. This effect is transient,
however, and presumably of insufficient duration to result in
significant tumor escape in our P815 GVL model.
Cosalane came to our group's attention during a search for
small-molecule antagonists of CCR7, a chemokine receptor
critical for aGVHD pathogenesis [5]. Nevertheless, cosalane's
mechanism of action in attenuating aGVHD is incompletely
understood. Previously, we demonstrated that CCR7¡/¡ Tcons
have an impaired ability to traffic to and expand within host
SLTs. This in turn results in reduced Tcon accumulation within
the colon and liver by the second post-transplantation week.
In the present study, cosalane-treated donor Tcons similarly
demonstrated an impaired ability to traffic into host SLTs early
after transplantation and accumulated to a lesser degree
within gastrointestinal and hepatic tissues by post-transplan-
tation day +14. Furthermore, studies using CCR7¡/¡ Tcons
showed that the compound is considerably less effective in
limiting aGVHD when donor Tcons lack this particular receptor.
Collectively, these data suggest that cosalane functions in a
CCR7-associated manner. Nevertheless, several of our findings
imply activity against other receptors beyond CCR7. Cosalane's
effects on Tcon trafficking into SLTs were rather modest, with
treated and untreated cells accumulating to similar degrees
within host ILNs, MLNs, and spleen by post-transplantation
day +7. Furthermore, cosalane demonstrated some residual
efficacy in limiting aGVHD even when donor Tcons were
knocked out at CCR7.
As noted above, cosalane was originally developed as an
antiviral agent; however, it was also shown to block CCR1-
dependent chemotaxis in response to CCL5 (RANTES) [18]. This
is potentially quite relevant to our own findings, because CCR1
was previously shown to be critical for gastrointestinal aGVHD
in mouse transplantation models [19]. Cosalane's effects on
other chemokine receptors are not well described and will be
the focus of ongoing mechanistic studies. Nevertheless, based
on currently available evidence, we suspect that cosalane lim-
its aGVHD through its effects on CCR7 and 1 or more inflam-
matory chemokine receptors, which may include CCR1.
Cosalane is a poor membrane penetrator and appears to
imbed in the outer leaflet of artificial phospholipid bilayers by
way of its cholestane moiety [20]. Thus, given its negatively
charged carboxylic head groups, it is possible that cosalane
could exert its effects at the cell surface via completely nonspe-
cific charge alterations, resulting in impaired cell adhesion,
changes in cell shape, or generally impaired receptor signaling.
Alternatively, the cholestane portion of the molecule conceiv-
ably could modify membrane fluidity and thus affect cell func-
tion in another nonspecific manner. Multiple findings would
seem to argue against either possibility, however. In previous
work, we examined the ability of a range of different choles-
terol derivatives to block CCR7-dependent chemotaxis. All
were found to be inactive, arguing against a nonspecific sterol
effect on the membrane. Furthermore, we demonstrated that
cosalane itself was approximately 10-fold more active against
CCL19 compared with CCL21, indicating that the nature of the
particular receptor ligand is important for the compound's
action [5]. Similarly, in previous work describing cosalane’s
ability to block CCR1, the identity of the chemokine agonist
critically influenced the compound's efficacy. Specifically, cosa-
lane blocked CCR1-dependent chemotaxis in response to CCL5
but was inactive against the receptor's other 2 ligands, CCL3
and CCL418. Moreover, in the present study, cosalane's abilityto prevent aGVHD after HSCT appeared to be linked to CCR7.
Collectively, these findings indicate a complex range of activi-
ties that likely extend beyond a single target but appear to be
confined to a limited number of particular receptor/ligand
pairs.
We believe that our present study has several strengths.
First, to our knowledge, it is the first study to demonstrate effi-
cacy of cosalane in a relevant preclinical animal model against
any disease process. Second, it is the first to demonstrate that a
CCR7 small-molecule antagonist can limit aGVHD. Third, we
used two separate murine allogeneic HSCT models, as well as a
xenogeneic system, to evaluate cosalane's anti-aGVHD effects.
This allowed us to realistically conclude that the compound's
actions are not strain-specific, and that its benefits are not lim-
ited to murine immune cells.
Nonetheless, this study has several limitations. Cosalane
and its derivatives are not commercially available, and thus
drug supply was a frequent issue. As a result, our n values are
somewhat small for some of the transplantation work. Further-
more, as described above, we are only able to describe a partial
mechanism for cosalane's activity in the HSCT setting at the
present time.
In summary, the existing antiviral drug cosalane demon-
strates an intriguing ability to limit aGVHD while appearing to
generally spare GVL effects when applied to donor Tcons before
transplantation. Although we are cautiously optimistic about
cosalane's therapeutic potential, additional work is needed to
develop a better understanding of the compound's mechanism
(s) of action and its off-target effects. These studies will be criti-
cal before any attempt is made to advance the drug to early-
phase clinical trials.
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